Information Provided By: 
Fly News Breaks for July 22, 2016
DXCM
Jul 22, 2016 | 07:50 EDT
Oppenheimer analyst Steven Lichtman raised his price target for Dexcom to $93 from $80 following the FDA's Clinical Chemistry and Clinical Toxicology panel vote in favor of non-adjunctive-use of the company's G5 CGM for insulin dosing decisions. While the FDA does not have to follow panel recommendations, the analyst believes it likely will. Oppenheimer has a Perform rating on the shares.
News For DXCM From the Last 2 Days
DXCM
Apr 26, 2024 | 16:08 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
DXCM
Apr 26, 2024 | 12:03 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
DXCM
Apr 26, 2024 | 09:14 EDT
DXCM
Apr 26, 2024 | 07:45 EDT
Canaccord analyst William Plovanic raised the firm's price target on DexCom to $145 from $144 and keeps a Buy rating on the shares. The firm said they reported a slight;ly better than expected Q1 as the company raised the low-end and mid-point of its revenue guidance and reiterated its adjusted GM/OM/EBITDA margins for 2024.
DXCM
Apr 25, 2024 | 17:21 EDT
Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSSnap (SNAP) up... To see the rest of the story go to thefly.com. See Story Here
DXCM
Apr 25, 2024 | 16:05 EDT
DXCM
Apr 25, 2024 | 16:04 EDT
DXCM
Apr 25, 2024 | 15:11 EDT
Pre-earnings options volume in DexCom is 11.4x normal with calls leading puts 11:2. Implied volatility suggests the market is anticipating a move near 5.8%, or $8.05, after results are released. Median move over the past eight quarters is 5.4%.
DXCM
Apr 25, 2024 | 13:09 EDT
